CDKL5 Deficiency Disorder Treatment Market: By Therapies (First Line Therapy (Antiepileptic Drugs and Anticonvulsant Drugs), Second line Therapies), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography (North America, Europe, Asia Pacific, Latin America, and MEA) and Forecast to 2029

CDKL5 Deficiency Disorder Treatment Market was valued at USD 10.5 million in 2022 and is poised to grow at a CAGR of  8.5% from 2023 to 2029. According to the National Institutes of Health, CDKL5 deficiency disorder is a genetic disorder that causes seizures, developmental delay, and severe intellectual disability. Seizures typically begin within a few months after birth and are difficult to control with medications. Increased awareness of such treatment and availability of first-line drugs in the market such as antileptic and anticonvulsant drugs which help to the patient for an easy cure, the growing incidence of CDKL across the world, increasing research and development drive the market, rare patient, and fewer clinical trials on CDKL5 drugs are the major restraints in the market. Frequency. CDKL5 deficiency disorder appears to be a rare condition with an incidence of 1 in 40,000 to 60,000 newborns. About 90 percent of those diagnosed with CDKL5 deficiency disorder are girls, making it one of the most common forms of genetic epilepsy. The CDKL5 gene provides instructions for making proteins that are essential for normal brain and neuron development.  

CDKL5 Deficiency Disorder Treatment Market Key Developments:

In March 2022, Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder. ZTALMY® (ganaxolone) is an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD), a rare form of genetic epilepsy, in patients two years of age and older, ZTALMY® is a neuroactive steroid that acts as a positive allosteric modulator of the GABAA receptor.